The FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the drug – widely used as a wrinkle treatment – in therapeutic indications.

The most commonly reported use of botulinum toxin among these cases was treatment of limb muscle spasticity associated with cerebral palsy. For Botox ... numbness of the lower extremities.

overactive bladder and lower limb spasticity. Botox (onabotulinumtoxinA) could be threatened by biosimilars in the coming years, as Mylan has this year received confirmation from the FDA that it ...

“This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option,” explains ...

In addition, Botox also has FDA approval for use in children ages 2 years or older for upper limb spasticity. It also has FDA approval for treating crossed eyes for a child who is 12 years or older.

Incobotulinumtoxin A is under clinical development by Merz Therapeutics and currently in Phase I for Unspecified Dermatological Disorders.

Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, announced that Health Canada approved Xeomin (incobotulinumtoxinA) for the treatment of post-stroke lower limb ...

BURLINGTON, Ontario, December 17, 2024--(BUSINESS WIRE)--Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ...